ArticleFrontiers in immunology2025
Antibodies to myelin oligodendrocyte glycoprotein in optic perineuritis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical risk factors for recurrence in adult-onset myelin oligodendrocyte glycoprotein antibody-associated optic neuritis.BMC ophthalmology · 2026Article
- Bilateral optic perineuritis with vestibulocochlear involvement: revisiting a rarely performed biopsy.Free neuropathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study aimed to investigate the prevalence of myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) in patients with optic perineuritis (OPN) and to analyze the clinical characteristics and prognosis of MOG-IgG-seropositive cases. Methods: A retrospective review was conducted of OPN patients diagnosed at the Neuro-ophthalmology Department of the Chinese People's Liberation Army (PLA) General Hospital between January 2020 and February 2023. Patients were classified into MOG-IgG-positive and seronegative groups based on cell-based assay (CBA) results. Demographic data, clinical manifestations, and visual outcomes were compared between the two groups. Results: A total of 33 patients (44 eyes) were included, with a mean onset age of 32.7 years (range 6-79) and a male-to-female ratio of 1:2. Bilateral involvement was observed in 33.3% of cases. Eye pain and optic disc swelling were present in 72.7% and 75.8% of patients, respectively. MOG-IgG was detected in 8 patients (24.2%). Compared with seronegative OPN, MOG-IgG-positive patients were significantly younger (mean age 20.8 years vs. 36.6 years, P = 0.034) and had a higher annual relapse rate (median 1.19 vs. 0.31, P = 0.008). All MOG-IgG-positive patients achieved visual acuity (VA) ≥20/40 after the first episode (100.0% vs. 45.5% in seronegative cases, P = 0.005), with this difference persisting at final follow-up (78.6% vs. 47.4%, P = 0.044). Discussion: These findings highlight distinct clinical characteristics of MOG-IgG-positive OPN, including younger age, higher relapse rates, and superior visual recovery. Detection of MOG-IgG in OPN may facilitate early diagnosis, prognosis prediction, and guide individualized therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.